CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to evaluate a potential vaccine for the Wuhan Coronavirus using Virus-Like Particle technology to enhance the immune response. The vaccine combines a generic VLP with a specific SARS-CoV-2 Spike protein antigen, targeting effective pre-clinical and clinical testing for safety and efficacy.
Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate.
The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen.
AdaptVac's VLP display technology has been shown to significantly improve vaccine immunogenicity, longevity and efficacy, for a wide range of viral and parasite diseases in pre-clinical studies (including flu and malaria). A unique feature of the technology is its two-component approa…
KOBENHAVNS UNIVERSITET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Denmark, Horsholm
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
UNIVERSITAETSKLINIKUM TUEBINGEN
Germany, TUEBINGEN
Type: Research institute
Activity type: Research Organisations
SME: No
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Horsholm
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
